FDA Approved: VRAYLAR — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VRYALR (cariprazine) by Allergan, Inc., granting changes to the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Schizophrenia

Drugs mentioned

• VRAYLAR (cariprazine)

Snippet

SUPPL AP for VRAYLAR (CARIPRAZINE)